Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction
Objectives: The objective of this study was to determine the cost-effectiveness and cost per
quality-adjusted life year (QALY) gained of sacubitril-valsartan relative to enalapril for …
quality-adjusted life year (QALY) gained of sacubitril-valsartan relative to enalapril for …
Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril/valsartan
Background Guidelines recommend targeting systolic blood pressure (SBP)< 130 mm Hg in
heart failure with preserved ejection fraction (HFpEF) with limited data. Objectives This study …
heart failure with preserved ejection fraction (HFpEF) with limited data. Objectives This study …
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial
Aim We assessed a subset of the 5040 patients in VICTORIA receiving sacubitril/valsartan,
either at randomization (n= 731) or post‐randomization drop‐in use (n= 425), to evaluate the …
either at randomization (n= 731) or post‐randomization drop‐in use (n= 425), to evaluate the …
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens
Aims To assess the tolerability of initiating/uptitrating sacubitril/valsartan (LCZ696) from 50 to
200 mg twice daily (target dose) over 3 and 6 weeks in heart failure (HF) patients (ejection …
200 mg twice daily (target dose) over 3 and 6 weeks in heart failure (HF) patients (ejection …
Sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction
Background Frailty is an increasingly common problem, and frail patients are less likely to
receive new pharmacologic therapies because the risk–benefit profile is perceived to be …
receive new pharmacologic therapies because the risk–benefit profile is perceived to be …
Reverse remodeling in heart failure with intensification of vasodilator therapy
TB Levine, AB Levine, SJ Keteyian, B Narins… - Clinical …, 1997 - Wiley Online Library
Background: Heart failure therapy with beta‐receptor blockade has been shown to effect a
partial reversal of left ventricular (LV) remodeling in heart failure. Hypothesis: We tested the …
partial reversal of left ventricular (LV) remodeling in heart failure. Hypothesis: We tested the …
Association between angiotensin receptor–neprilysin inhibition, cardiovascular biomarkers, and cardiac remodeling in heart failure with reduced ejection fraction
Background: Sacubitril/valsartan (S/V) treatment is associated with reverse cardiac
remodeling and reductions in biomarkers reflecting ventricular wall stress and myocardial …
remodeling and reductions in biomarkers reflecting ventricular wall stress and myocardial …